Catabasis Shares Its Latest Edition of Catabasis Connection

Catabasis Pharmaceuticals’ Phase 3 PolarisDMD trial is enrolling the expected patient population and they are partnering with Duchenne UK to evaluate edasalonexent in non-ambulatory boys and men affected by Duchenne. Read all about these activities and more in their latest newsletter here. You can hear directly from them in person at our Worcester Family Workshop on January 25, 2020. Register for the workshop today.